|
1
|
Nio K, Yamashita T and Kaneko S: The
evolving concept of liver cancer stem cells. Mol Cancer. 16:42017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhu CP, Wang AQ, Zhang HH, Wan XS, Yang
XB, Chen SG and Zhao HT: Research progress and prospects of markers
for liver cancer stem cells. World J Gastroenterol. 21:12190–12196.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee TK, Cheung VC and Ng IO: Liver
tumor-initiating cells as a therapeutic target for hepatocellular
carcinoma. Cancer Lett. 338:101–109. 2013. View Article : Google Scholar
|
|
4
|
Liu LL, Fu D, Ma Y and Shen XZ: The power
and the promise of liver cancer stem cell markers. Stem Cells Dev.
20:2023–2030. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salnikov AV, Kusumawidjaja G, Rausch V,
Bruns H, Gross W, Khamidjanov A, Ryschich E, Gebhard MM,
Moldenhauer G, Büchler MW, et al: Cancer stem cell marker
expression in hepatocellular carcinoma and liver metastases is not
sufficient as single prognostic parameter. Cancer Lett.
275:185–193. 2009. View Article : Google Scholar
|
|
6
|
Dollé L, Theise ND, Schmelzer E, Boulter
L, Gires O and van Grunsven LA: EpCAM and the biology of hepatic
stem/progenitor cells. Am J Physiol Gastrointest Liver Physiol.
308:G233–G250. 2015. View Article : Google Scholar :
|
|
7
|
Yamashita T, Ji J, Budhu A, Forgues M,
Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al:
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating
cells with stem/progenitor cell features. Gastroenterology.
136:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Simpson AJ, Caballero OL, Jungbluth A,
Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and
cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cronwright G, Le Blanc K, Götherström C,
Darcy P, Ehnman M and Brodin B: Cancer/testis antigen expression in
human mesenchymal stem cells: Down-regulation of SSX impairs cell
migration and matrix metalloproteinase 2 expression. Cancer Res.
65:2207–2215. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saldanha-Araujo F, Haddad R, Zanette DL,
De Araujo AG, Orellana MD, Covas DT, Zago MA and Panepucci RA:
Cancer/Testis antigen expression on mesenchymal stem cells isolated
from different tissues. Anticancer Res. 30:5023–5027.
2010.PubMed/NCBI
|
|
11
|
Wen J, Li H, Tao W, Savoldo B, Foglesong
JA, King LC, Zu Y and Chang CC: High throughput quantitative
reverse transcription PCR assays revealing over-expression of
cancer testis antigen genes in multiple myeloma stem cell-like side
population cells. Br J Haematol. 166:711–719. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin B, Zeng Y, Liu G, Wang X, Wang P and
Song Y: MAGE-A3 is highly expressed in a cancer stem cell-like side
population of bladder cancer cells. Int J Clin Exp Pathol.
7:2934–2941. 2014.PubMed/NCBI
|
|
13
|
Yamada R, Takahashi A, Torigoe T, Morita
R, Tamura Y, Tsukahara T, Kanaseki T, Kubo T, Watarai K, Kondo T,
et al: Preferential expression of cancer/testis genes in cancer
stem-like cells: Proposal of a novel sub-category,
cancer/testis/stem gene. Tissue Antigens. 81:428–434. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soulez M, Saurin AJ, Freemont PS and
Knight JC: SSX and the synovial-sarcoma-specific chimaeric protein
SYT-SSX co-localize with the human Polycomb group complex.
Oncogene. 18:2739–2746. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weon JL and Potts PR: The MAGE protein
family and cancer. Curr Opin Cell Biol. 37:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jia HL, Ye QH, Qin LX, Budhu A, Forgues M,
Chen Y, Liu YK, Sun HC, Wang L, Lu HZ, et al: Gene expression
profiling reveals potential biomarkers of human hepatocellular
carcinoma. Clin Cancer Res: an official journal of the American
Association for Cancer Research. 13:pp. 1133–1139. 2007, https://doi.org/10.1158/1078-0432.CCR-06-1025.
View Article : Google Scholar
|
|
17
|
Picard V, Bergeron A, Larue H and Fradet
Y: MAGE-A9 mRNA and protein expression in bladder cancer. Int J
Cancer. 120:2170–2177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bergeron A, Picard V, LaRue H, Harel F,
Hovington H, Lacombe L and Fradet Y: High frequency of MAGE-A4 and
MAGE-A9 expression in high-risk bladder cancer. Int J Cancer.
125:1365–1371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu X, Tang X, Lu M, Tang Q, Zhang H, Zhu
H, Xu N, Zhang D, Xiong L, Mao Y, et al: Overexpression of MAGE-A9
predicts unfavorable outcome in breast cancer. Exp Mol Pathol.
97:579–584. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hou SY, Sang MX, Geng CZ, Liu WH, Lü WH,
Xu YY and Shan BE: Expressions of MAGE-A9 and MAGE-A11 in breast
cancer and their expression mechanism. Arch Med Res. 45:44–51.
2014. View Article : Google Scholar
|
|
21
|
Zhang S, Zhai X, Wang G, Feng J, Zhu H, Xu
L, Mao G and Huang J: High expression of MAGE-A9 in tumor and
stromal cells of non-small cell lung cancer was correlated with
patient poor survival. Int J Clin Exp Pathol. 8:541–550.
2015.PubMed/NCBI
|
|
22
|
Han L, Jiang B, Wu H, Zhang S and Lu X:
Expression and prognostic value of MAGE-A9 in laryngeal squamous
cell carcinoma. Int J Clin Exp Pathol. 7:6734–6742. 2014.PubMed/NCBI
|
|
23
|
Hatiboglu G, Pritsch M, Macher-Goeppinger
S, Zöller M, Huber J, Haferkamp A, Pahernik S, Wagener N and
Hohenfellner M: Prognostic value of melanoma-associated antigen A9
in renal cell carcinoma. Scand J Urol. 47:311–322. 2013. View Article : Google Scholar
|
|
24
|
Gu X, Fu M, Ge Z, Zhan F, Ding Y, Ni H,
Zhang W, Zhu Y, Tang X, Xiong L, et al: High expression of MAGE-A9
correlates with unfavorable survival in hepatocellular carcinoma.
Sci Rep. 4:66252014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
van Duin M, Broyl A, de Knegt Y,
Goldschmidt H, Richardson PG, Hop WC, van der Holt B,
Joseph-Pietras D, Mulligan G, Neuwirth R, et al: Cancer testis
antigens in newly diagnosed and relapse multiple myeloma:
Prognostic markers and potential targets for immunotherapy.
Haematologica. 96:1662–1669. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu Y, Wang C, Zhang Y, Jia L and Huang J:
Overexpression of MAGE-A9 is predictive of poor prognosis in
epithelial ovarian cancer. Sci Rep. 5:121042015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamashita T, Forgues M, Wang W, Kim JW, Ye
Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, et al: EpCAM and
alpha-fetoprotein expression defines novel prognostic subtypes of
hepatocellular carcinoma. Cancer Res. 68:1451–1461. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yue W, Jiao F, Liu B, You J and Zhou Q:
Enrichment and function research of large cell lung cancer stem
cell-like cells. Zhongguo Fei Ai Za Zhi. 14:484–491. 2011.In
Chinese. PubMed/NCBI
|
|
29
|
Yoshida S, Shimmura S, Shimazaki J,
Shinozaki N and Tsubota K: Serum-free spheroid culture of mouse
corneal keratocytes. Invest Ophthalmol Vis Sci. 46:1653–1658. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamashita T, Budhu A, Forgues M and Wang
XW: Activation of hepatic stem cell marker EpCAM by
Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res.
67:10831–10839. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kimura O, Takahashi T, Ishii N, Inoue Y,
Ueno Y, Kogure T, Fukushima K, Shiina M, Yamagiwa Y, Kondo Y, et
al: Characterization of the epithelial cell adhesion molecule
(EpCAM)+ cell population in hepatocellular carcinoma
cell lines. Cancer Sci. 101:2145–2155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhan W, Zhang Z, Zhang Y, Ma J, Wu T, Gu
Y, Li Y and Yang J: Prognostic value of MAGE-A9 expression in
patients with colorectal cancer. Clin Res Hepatol Gastroenterol.
40:239–245. 2016. View Article : Google Scholar
|
|
33
|
Zhai X, Xu L, Zhang S, Zhu H, Mao G and
Huang J: High expression levels of MAGE-A9 are correlated with
unfavorable survival in lung adenocarcinoma. Oncotarget.
7:4871–4881. 2016. View Article : Google Scholar :
|
|
34
|
Liu S, Sang M, Xu Y, Gu L, Liu F and Shan
B: Expression of MAGE-A1, -A9, -A11 in laryngeal squamous cell
carcinoma and their prognostic significance: A retrospective
clinical study. Acta Otolaryngol. 136:506–513. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thorgeirsson SS: Stemness in liver cancer.
Dig Dis. 35:387–389. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang X, Wang L, Liu M and Li D:
CRISPR/Cas9 system: A powerful technology for in vivo and ex vivo
gene therapy. Sci China Life Sci. 60:468–475. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sachdeva M, Sachdeva N, Pal M, Gupta N,
Khan IA, Majumdar M and Tiwari A: CRISPR/Cas9: Molecular tool for
gene therapy to target genome and epigenome in the treatment of
lung cancer. Cancer Gene Ther. 22:509–517. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schwarzenbach H, Eichelser C, Steinbach B,
Tadewaldt J, Pantel K, Lobanenkov V and Loukinov D: Differential
regulation of MAGE-A1 promoter activity by BORIS and Sp1, both
interacting with the TATA binding protein. BMC Cancer. 14:7962014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wischnewski F, Pantel K and Schwarzenbach
H: Promoter demethylation and histone acetylation mediate gene
expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells.
Mol Cancer Res. 4:339–349. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang B, Wu J, Maddodi N, Ma Y, Setaluri V
and Longley BJ: Epigenetic control of MAGE gene expression by the
KIT tyrosine kinase. J Invest Dermatol. 127:2123–2128. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kondo T, Zhu X, Asa SL and Ezzat S: The
cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel
target of fibroblast growth factor receptor 2-IIIb through histone
H3 modifications in thyroid cancer. Clin Cancer Res. 13:4713–4720.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu W, Cheng S, Asa SL and Ezzat S: The
melanoma-associated antigen A3 mediates fibronectin-controlled
cancer progression and metastasis. Cancer Res. 68:8104–8112. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Doyle JM, Gao J, Wang J, Yang M and Potts
PR: MAGE-RING protein complexes comprise a family of E3 ubiquitin
ligases. Mol Cell. 39:963–974. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang B, O'Herrin SM, Wu J, Reagan-Shaw S,
Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, et
al: MAGE-A, mMage-B, and MAGE-C proteins form complexes with KAP1
and suppress p53-dependent apoptosis in MAGE-positive cell lines.
Cancer Res. 67:9954–9962. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pineda CT, Ramanathan S, Fon Tacer K, Weon
JL, Potts MB, Ou YH, White MA and Potts PR: Degradation of AMPK by
a cancer-specific ubiquitin ligase. Cell. 160:715–728. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hardie DG: Molecular pathways: Is AMPK a
friend or a foe in cancer? Clin Cancer Res. 21:3836–3840. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Choudhury Y, Salt IP and Leung HY:
AMPK-friend or foe for targeted therapy? Cell Cycle. 14:1761–1762.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kasznicki J, Sliwinska A and Drzewoski J:
Metformin in cancer prevention and therapy. Ann Transl Med.
2:572014.PubMed/NCBI
|
